CSL
First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark
January 21, 2025Sales and Marketing CSL, Denmark, genetic, haemophilia, treatment
21 January 2025 – Copenhagen, Denmark – CSL Behring Denmark today announced that the first Danish patients with haemophilia B …
FDA approves CSL haemophilia A drug
May 26, 2016Sales and Marketing CSL, afstyla, haemophilia a, treatment
CSL (ASX: CSL) has announced that the US Food and Drug Administration (FDA) has approved Afstyla (antihaemophilic factor [recombinant), single …
CSL’s flu vaccine scores FDA approval
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing CSL, FDA, Vaccine, flu, four strain, four-strain, influenza, influenza a, influenza b, seqirus
Seqirus, a division of CSL, has announced that the US Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent (influenza …
EU approves Idelvion for haemophilia B treatment
May 13, 2016Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B
The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with …
CSL completes $275m Novartis vaccines acquisition
August 3, 2015Manufacturing and Production, Sales and Marketing CSL, Novartis, acquisitions, asset swap, vaccines
CSL Limited has finalised its transaction to acquire Novartis’s global influenza vaccine business for $275 million. The move means Novartis …
CSL vaccine plant cited in FDA letter
July 1, 2010Manufacturing and Production CSL, GMP, P&G, manufacturing compliance
CSL Biotherapies has been sent a letter by the US Food and Drug Administration which indicates that vials of seasonal …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
